Antioxidant therapy for lung injury

Lung Injury: Mechanisms, Pathophysiology, and Therapy

Volumn , Issue , 2005, Pages 665-703

  Asikainen, Tiina M ^a,b   White, Carl W ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 28344454765     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (225)

1. Turrens JF. Superoxide production by the mitochondrial respiratory chain. Biosci Rep 1997; 17:3-8.
2. Freeman BA, Crapo JD. Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria. J Biol Chem 1981; 256:10986-10992.
3. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine Oxford: Clarendon Press, 1989.
4. Budinger GR, Tso M, McClintock DS, Dean DA, Sznajder JI, Chandel NS. Hyperoxia-induced apoptosis does not require mitochondrial reactive oxygen species and is regulated by Bcl-2 proteins. J Biol Chem 2002; 277: 15654-15660.
5. Kinnula VL, Crapo JD, Raivio KO. Generation and disposal of reactive oxygen metabolites in the lung. Lab Invest 1995; 73:3-19.
6. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982; 47:412-426.
7. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000; 279:L1005-L1028.
8. Sies H. Oxidative stress: from basic research to clinical application. Am J Med 1991; 91:31S-38S.
9. Fridovich I, Freeman B. Antioxidant defenses in the lung. Annu Rev Physiol 1986; 48:693-702.
10. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 2001; 41:261-295.
11. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res 1999; 31:261-272.
12. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979; 59:527-605.
13. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther 1991; 51:155-194.
14. Kinnula VL, Crapo JD. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med 2003; 167:1600-1619.
15. Hass MA, Massaro D. Developmental regulation of rat lung Cu, Zn-superoxide dismutase. Biochem J 1987; 246:697-703.
16. Rickett GM, Kelly FJ. Developmental expression of antioxidant enzymes in guinea pig lung and liver. Development 1990; 108:331-336.
17. Walther FJ, Wade AB, Warburton D, Forman HJ. Ontogeny of antioxidant enzymes in the fetal lamb lung. Exp Lung Res 1991; 17:39-45.
18. Kim HS, Kang SW, Rhee SG, Clerch LB. Rat lung peroxiredoxins I and II are differentially regulated during development and by hyperoxia. Am J Physiol Lung Cell Mol Physiol 2001; 280:L1212-L1217.
19. Frank L, Sosenko IR. Failure of premature rabbits to increase antioxidant enzymes during hyperoxic exposure: increased susceptibility to pulmonary oxygen toxicity compared with term rabbits. Pediatr Res 1991; 29:292-296.
20. Morton RL, Das KC, Guo XL, Ikle DN, White CW. Effect of oxygen on lung superoxide dismutase activities in premature baboons with bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 1999; 276:L64-L74.
21. Frank L. Developmental aspects of experimental pulmonary oxygen toxicity. Free Radic Biol Med 1991; 11:463-494.
22. Yam J, Frank L, Roberts RJ. Oxygen toxicity: comparison of lung biochemical responses in neonatal and adult rats. Pediatr Res 1978; 12:115-119.
23. 2. Am J Physiol 1987; 252:R693-R698.
24. Chen Y, Whitney PL, Frank L. Comparative responses of premature vs. full-term newborn rats to prolonged hyperoxia. Pediatr Res 1994; 35:233-237.
25. 2tolerance in rabbits with no increase in antioxidant enzymes. J Appl Physiol 1989; 66:1679-1684.
26. Kinnula VL, Pietarinen P, Aalto K, Virtanen I, Raivio KO. Mitochondrial superoxide dismutase induction does not protect epithelial cells during oxidant exposure in vitro. Am J Physiol Lung Cell Mol Physiol 1995; 268:L71-L77.
27. Allen CB, Guo XL, White CW. Changes in pulmonary expression of hexokinase and glucose transporter mRNAs in rats adapted to hyperoxia. Am J Physiol Lung Cell Mol Physiol 1998; 274:L320-L329.
28. White CW, Greene KE, Allen CB, Shannon JM. Elevated expression of surfactant proteins in newborn rats during adaptation to hyperoxia. Am J Respir Cell Mol Biol 2001; 25:51-59.
29. McElroy MC, Postle AD, Kelly FJ. Catalase, superoxide dismutase and glutathione peroxidase activities of lung and liver during human development. Biochim Biophys Acta 1992; 15:153-158.
30. Asikainen TM, Raivio KO, Saksela M, Kinnula VL. Expression and developmental profile of antioxidant enzymes in human lung and liver. Am J Respir Cell Mol Biol 1998; 19:942-949.
31. Strange RC, Cotton W, Fryer AA, Drew R, Bradwell AR, Marshall T, Collins MF, Bell J, Hume R. Studies on the expression of Cu, Zn superoxide dismutase in human tissues during development. Biochim Biophys Acta 1988; 964:260-265.
32. Strange RC, Cotton W, Fryer AA, Jones P, Bell J, Hume R. Lipid peroxidation and expression of copper-zinc and manganese superoxide dismutase in lungs of premature infants with hyaline membrane disease and bronchopulmonary dysplasia. J Lab Clin Med 1990; 116:666-673.
33. Asikainen TM, Heikkilä P, Kaarteenaho-Wiik R, Kinnula VL, Raivio KO. Cell-specific expression of manganese superoxide dismutase protein in the lungs of patients with respiratory distress syndrome, chronic lung disease, or persistent pulmonary hypertension. Pediatr Pulmonol 2001; 32:193-200.
34. Jain A, Mehta T, Auld PA, Rodrigues J, Ward RF, Schwartz MK, Martensson J. Glutathione metabolism in newborns: evidence for glutathione deficiency in plasma, bronchoalveolar lavage fluid, and lymphocytes in prematures. Pediatr Pulmonol 1995; 20:160-166.
35. Levonen AL, Lapatto R, Saksela M, Raivio KO. Expression of gamma-glutamylcysteine synthetase during development. Pediatr Res 2000; 47:266-270.
36. Viña J, Vento M, Garcia-Sala F, Puertes IR, Gasco E, Sastre J, Asensi M, Pallardo FV. l-Cysteine and glutathione metabolism are impaired in premature infants due to cystathionase deficiency. Am J Clin Nutr 1995; 61: 1067-1069.
37. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163:1723-1729.
38. Northway WJ, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276:357-368.
39. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988; 82:527-532.
40. deLemos RA, Coalson JJ. The contribution of experimental models to our understanding of the pathogenesis and treatment of bronchopulmonary dysplasia. Clin Perinatol 1992; 19:521-539.
41. Anderson WR, Strickland MB, Tsai SH, Haglin JJ. Light microscopic and ultrastructural study of the adverse effects of oxygen therapy on the neonate lung. Am J Pathol 1973; 73:327-348.
42. Crapo JD. Morphologic changes in pulmonary oxygen toxicity. Annu Rev Physiol 1986; 48:721-731.
43. Margraf LR, Tomashefski JF Jr, Bruce MC, Dahms BB. Morphometric analysis of the lung in bronchopulmonary dysplasia. Am Rev Respir Dis 1991; 143:391-400.
44. Saugstad OD. Chronic lung disease: the role of oxidative stress. Biol Neonate 1998; 1:21-28.
45. Gitto E, Reiter RJ, Karbownik M, Xian-Tan D, Barberi I. Respiratory distress syndrome in the newborn: role of oxidative stress. Intensive Care Med 2001; 27:1116-1123.
46. Pitkänen OM, Hallman M, Andersson SM. Correlation of free oxygen radical-induced lipid peroxidation with outcome in very low birth weight infants. J Pediatr 1990; 116:760-764.
47. Varsila E, Pesonen E, Andersson S. Early protein oxidation in the neonatal lung is related to development of chronic lung disease. Acta Pediatr 1995; 84:1296-1299.
48. Banks BA, Ischiropoulos H, McClelland M, Ballard PL, Ballard RA. Plasma 3-nitrotyrosine is elevated in premature infants who develop bronchopulmonary dysplasia. Pediatrics 1998; 101:870-874.
49. Grigg J, Barber A, Silverman M. Bronchoalveolar lavage fluid glutathione in intubated premature infants. Arch Dis Child 1993; 69:49-51.
50. Smith CV, Hansen TN, Martin NE, McMicken HW, Elliott SJ. Oxidant stress responses in premature infants during exposure to hyperoxia. Pediatr Res 1993; 34:360-365.
51. White CW, Stabler SP, Allen RH, Moreland S, Rosenberg AA. Plasma cysteine concentrations in infants with respiratory distress. J Pediatr 1994; 125:769-777.
52. Levin DL, Heymann MA, Kitterman JA, Gregory GA, Phibbs RH, Rudolph AM. Persistent pulmonary hypertension of the newborn infant. J Pediatr 1976; 89:626-630.
53. Kääpä P. Meconium aspiration syndrome: a role for phospholipase A2 in the pathogenesis? Acta Paediatr 2001; 90:365-367.
54. Chabot F, Mitchell JA, Gutteridge JM, Evans TW. Reactive oxygen species in acute lung injury. Eur Respir J 1998; 11:745-757.
55. Pacht ER, Timerman AP, Lykens MG, Merola AJ. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest 1991; 100:1397-1403.
56. Haddad IY, Pataki G, Hu P, Galliani C, Beckman JS, Matalon S. Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. J Clin Invest 1994; 94:2407-2413.
57. Metnitz PG, Bartens C, Fischer M, Fridrich P, Steltzer H, Druml W. Antioxidant status in patients with acute respiratory distress syndrome. Intensive Care Med 1999; 25:180-185.
58. Barnes PJ. Pathophysiology of asthma. Br J Clin Pharmacol 1996; 42:3-10.
59. Jarjour NN, Calhoun WJ. Enhanced production of oxygen radicals in asthma. J Lab Clin Med 1994; 123:131-136.
60. Vachier I, Damon M, Le Doucen C, de Paulet AC, Chanez P, Michel FB, Godard P. Increased oxygen species generation in blood monocytes of asthmatic patients. Am Rev Respir Dis 1992; 146:1161-1166.
61. De Raeve HR, Thunnissen FB, Kaneko FT, Guo FH, Lewis M, Kavuru MS, Secic M, Thomassen MJ, Erzurum SC. Decreased Cu, Zn-SOD activity in asthmatic airway epithelium: correction by inhaled corticosteroid in vivo. Am J Physiol Lung Cell Mol Physiol 1997; 272:L148-L154.
62. Smith LJ, Shamsuddin M, Sporn PH, Denenberg M, Anderson J. Reduced superoxide dismutase in lung cells of patients with asthma. Free Radic Biol Med 1997; 22:1301-1307.
63. Comhair SA, Bhathena PR, Dweik RA, Kavuru M, Erzurum SC. Rapid loss of superoxide dismutase activity during antigen-induced asthmatic response. Lancet 2000; 355:624.
64. Larsen GL, White CW, Takeda K, Loader JE, Nguyen DD, Joetham A, Groner Y, Gelfand EW. Mice that overexpress Cu=Zn superoxide dismutase are resistant to allergen-induced changes in airway control. Am J Physiol Lung Cell Mol Physiol 2000; 279:L350-L359.
65. Comhair SA, Bhathena PR, Farver C, Thunnissen FB, Erzurum SC. Extracellular glutathione peroxidase induction in asthmatic lungs: evidence for redox regulation of expression in human airway epithelial cells. FASEB J 2001; 15:70-78.
66. Smith LJ, Houston M, Anderson J. Increased levels of glutathione in bronchoalveolar lavage fluid from patients with asthma. Am Rev Respir Dis 1993; 147:1461-1464.
67. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000; 117:10S-14S.
68. Rahman I, MacNee W. Role of oxidants=antioxidants in smoking-induced lung diseases. Free Radic Biol Med 1996; 21:669-681.
69. Langen RC, Korn SH, Wouters EF. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med 2003; 35:226-235.
70. Church DF, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 1985; 64:111-126.
71. Rahman I, MacNee W. Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease. Am J Physiol Lung Cell Mol Physiol 1999; 277:L1067-L1088.
72. McCusker K, Hoidal J. Selective increase of antioxidant enzyme activity in the alveolar macrophages from cigarette smokers and smoke-exposed hamsters. Am Rev Respir Dis 1990; 141:678-682.
73. Kondo T, Tagami S, Yoshioka A, Nishimura M, Kawakami Y. Current smoking of elderly men reduces antioxidants in alveolar macrophages. Am J Respir Crit Care Med 1994; 149:178-182.
74. Gilks CB, Price K, Wright JL, Churg A. Antioxidant gene expression in rat lung after exposure to cigarette smoke. Am J Pathol 1998; 152:269-278.
75. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996; 154: 1055-1060.
76. Strausz J, Muller-Quernheim J, Steppling H, Ferlinz R. Oxygen radical production by alveolar inflammatory cells in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1990; 141:124-128.
77. Lakari E, PääkköP, Kinnula VL. Manganese superoxide dismutase, but not Cu-Zn superoxide dismutase, is highly expressed in the granulomas of pulmonary sarcoidosis and extrinsic allergic alveolitis. Am J Respir Crit Care Med 1998; 158:589-596.
78. Lakari E, PääkköP, Pietarinen-Runtti P, Kinnula VL. Manganese superoxide dismutase and catalase are coordinately expressed in the alveolar region in chronic interstitial pneumonias and granulomatous diseases of the lung. Am J Respir Crit Care Med 2000; 161:615-621.
79. Kinnula VL. Oxidant and antioxidant mechanisms of lung disease caused by asbestos fibres. Eur Respir J 1999; 14:706-716.
80. Janssen YM, Marsh JP, Absher MP, Hemenway D, Vacek PM, Leslie KO, Borm PJ, Mossman BT. Expression of antioxidant enzymes in rat lungs after inhalation of asbestos or silica. J Biol Chem 1992; 267:10625-10630.
81. Pron G, Mahrour N, Orlowski S, Tounekti O, Poddevin B, Belehradek J Jr, Mir LM. Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem Pharmacol 1999; 57:45-56.
82. Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol 1992; 19:3-8.
83. Smith LL. Mechanism of paraquat toxicity in lung and its relevance to treatment. Hum Toxicol 1987; 6:31-36.
84. Saugstad OD. Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Pediatrics 1996; 98:103-107.
85. Lynch MJ, Grum CM, Gallagher KP, Bolling SF, Deeb GM, Morganroth ML. Xanthine oxidase inhibition attenuates ischemic-reperfusion lung injury. J Surg Res 1988; 44:538-544.
86. Linder N, Rapola J, Raivio KO. Cellular expression of xanthine oxidoreductase protein in normal human tissues. Lab Invest 1999; 79:967-974.
87. Kinnula VL, Sarnesto A, Heikkilä L, Toivonen H, Mattila S, Raivio KO. Assessment of xanthine oxidase in human lung and lung transplantation. Eur Respir J 1997; 10:676-680.
88. Pesonen EJ, Linder N, Raivio KO, Sarnesto A, Lapatto R, Höckerstedt K, Mäkisalo H, Andersson S. Circulating xanthine oxidase and neutrophil activation during human liver transplantation. Gastroenterology 1998; 114: 1009-1015.
89. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxiareoxygenation injury. Am J Physiol Cell Physiol 2002; 282:C227-C241.
90. Gorecki M, Beck Y, Hartman JR, Fischer M, Weiss L, Tochner Z, Slavin S, Nimrod A. Recombinant human superoxide dismutases: production and potential therapeutical uses. Free Radic Res Commun 1991; 1:401-410.
91. Freeman BA, Young SL, Crapo JD. Liposome-mediated augmentation of superoxide dismutase in endothelial cells prevents oxygen injury. J Biol Chem 1983; 258:12534-12542.
92. 2injury. J Appl Physiol 1987; 63:359-367.
93. Walther FJ, David-Cu R, Supnet MC, Longo ML, Fan BR, Bruni R. Uptake of antioxidants in surfactant liposomes by cultured alveolar type II cells is enhanced by SP-A. Am J Physiol Lung Cell Mol Physiol 1993; 265: L330-L339.
94. Turrens JF, Crapo JD, Freeman BA. Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. J Clin Invest 1984; 73:87-95.
95. 2toxicity in the newborn rat. J Appl Physiol 1987; 63:347-352.
96. White CW, Jackson JH, Abuchowski A, Kazo GM, Mimmack RF, Berger EM, Freeman BA, McCord JM, Repine JE. Polyethylene glycol-attached antioxidant enzymes decrease pulmonary oxygen toxicity in rats. J Appl Physiol 1989; 66:584-590.
97. Jacobson JM, Michael JR, Jafri MH, Gurtner GH. Antioxidants and antioxidant enzymes protect against pulmonary oxygen toxicity in the rabbit. J Appl Physiol 1990; 68:1252-1259.
98. Inoue M. Targeting superoxide dismutase by gene and protein engineering. Methods Enzymol 1994; 233:212-221.
99. Padmanabhan RV, Gudapaty R, Liener IE, Schwartz BA, Hoidal JR. Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. Am Rev Respir Dis 1985; 132:164-167.
100. Davis JM, Rosenfeld WN, Sanders RJ, Gonenne A. Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury. J Appl Physiol 1993; 74:2234-2241.
101. Walther FJ, Nunez FL, David-Cu R, Hill KE. Mitigation of pulmonary oxygen toxicity in rats by intratracheal instillation of polyethylene glycolconjugated antioxidant enzymes. Pediatr Res 1993; 33:332-335.
102. Walther FJ, David-Cu R, Lopez SL. Antioxidant-surfactant liposomes mitigate hyperoxic lung injury in premature rabbits. Am J Physiol 1995; 269:L613-L617.
103. Simonson SG, Welty-Wolf KE, Huang YC, Taylor DE, Kantrow SP, Carraway MS, Crapo JD, Piantadosi CA. Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. I. Physiology and biochemistry. J Appl Physiol 1997; 83:550-558.
104. Welty-Wolf KE, Simonson SG, Huang YC, Kantrow SP, Carraway MS, Chang LY, Crapo JD, Piantadosi CA. Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. II. Morphometric analysis. J Appl Physiol 1997; 83:559-568.
105. Davis JM, Richter SE, Biswas S, Rosenfeld WN, Parton L, Gewolb IH, Parad R, Carlo W, Couser RJ, Baumgart S, Atluru V, Salerno L, Kassem N. Long-term follow-up of premature infants treated with prophylactic, intratracheal recombinant human Cu-Zn superoxide dismutase. J Perinatol 2000; 20:213-216.
106. Tamagawa K, Taooka Y, Maeda A, Hiyama K, Ishioka S, Yamakido M. Inhibitory effects of a lecithinized superoxide dismutase on bleomycininduced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2000; 161: 1279-1284.
107. Mossman BT, Marsh JP, Sesko A, Hill S, Shatos MA, Doherty J, Petruska J, Adler KB, Hemenway D, Mickey R et al. Inhibition of lung injury, inflammation, and interstitial pulmonary fibrosis by polyethylene glycol-conjugated catalase in a rapid inhalation model of asbestosis. Am Rev Respir Dis 1990; 141:1266-1271.
108. Patel M, Day BJ. Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmacol Sci 1999; 20:359-364.
109. AstonK, RathN, Naik A, SlomczynskaU, SchallOF, RileyDP. Computer-aided design (CAD) ofMn(II) complexes: superoxide dismutase mimetics with catalytic activity exceeding the native enzyme. Inorg Chem 2001; 40:1779-1789.
110. Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH, Wallace DC, Epstein CJ. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995; 11:376-381.
111. Lebovitz RM, Zhang H, Vogel H, Cartwright JJ, Dionne L, Lu N, Huang S, Matzuk MM. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide diamutase-deficient mice. Proc Natl Acad Sci USA 1996; 93:9782-9787.
112. Melov S, Coskun P, Patel M, Tuinstra R, Cottrell B, Jun AS, Zastawny TH, Dizdaroglu M, Goodman SI, Huang TT, Miziorko H, Epstein CJ, Wallace DC. Mitochondrial disease in superoxide dismutase 2 mutant mice. Proc Natl Acad Sci USA 1999; 96:846-851.
113. Melov S, Schneider JA, Day BJ, Hinerfeld D, Coskun P, Mirra SS, Crapo JD, Wallace DC. A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nat Genet 1998; 18:159-163.
114. Day BJ, Shawen S, Liochev SI, Crapo JD. A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury in vitro. J Pharmacol Exp Ther 1995; 275:1227-1232.
115. Day BJ, Crapo JD. A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced lung injury in vivo. Toxicol Appl Pharmacol 1996; 140:94-100.
116. Wilborn AM, Evers LB, Canada AT. Oxygen toxicity to the developing lung of the mouse: role of reactive oxygen species. Pediatr Res 1996; 40: 225-232.
117. Oury TD, Thakker K, Menache M, Chang LY, Crapo JD, Day BJ. Attenuation of bleomycin-induced pulmonary fibrosis by a catalytic antioxidant metalloporphyrin. Am J Respir Cell Mol Biol 2001; 25:164-169.
118. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Haberle I, White CR, Freeman BA. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 2001; 98: 15215-15220.
119. Tang K, Wagner PD, Breen EC. Lung-specific inactivation of VEGF in adult mice leads to emphysema like changes. [abstr]. Am J Respir Crit Care Med 2002; 165:8 (part 2 of 2), B54.
120. Tuder RM, Taraseviciene-Stewart L, Flores S, Salvemini D, Voelkel NF. M40419, a superoxide dismutase mimetic, prevents the development of emphysema induced by VEGF receptor blockade [abstr]. Am J Respir Crit Care Med 2002; 165:8 (part 2 of 2), A463.
121. Smith KR, Uyeminami DL, Kodavanti UP, Crapo JD, Chang L-Y, Pinkerton KE. Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic Biol Med. 2002; 15:1106-1114.
122. Gonzalez PK, Zhuang J, Doctrow SR, Malfroy B, Benson PF, Menconi MJ, Fink MP. Role of oxidant stress in the adult respiratory distress syndrome: evaluation of a novel antioxidant strategy in a porcine model of endotoxininduced acute lung injury. Shock 1996; 6:S23-S26.
123. Zhang M, Nomura A, Uchida Y, Iijima H, Sakamoto T, Iishii Y, Morishima Y, Mochizuki M, Masuyama K, Hirano K, Sekizawa K. Ebselen suppresses late airway responses and airway inflammation in guinea pigs. Free Radic Biol Med 2002; 32:454-464.
124. Cotgreave IA, Johansson U, Westergren G, Moldeus PW, Brattsand R. The anti-inflammatory activity of ebselen but not thiols in experimental alveolitis and bronchiolitis. Agents Actions 1988; 24:313-319.
125. Belvisi MG, Haddad EB, Battram C, Birrell M, Foster M, Webber S. Antiinflammatory properties of ebselen in a model of sephadex-induced lung inflammation. Eur Respir J 2000; 15:579-581.
126. Ishii Y, Hashimoto K, Hirano K, Morishima Y, Mochizuki M, Masuyama K, Nomura A, Sakamoto T, Uchida Y, Sagai M, Sekizawa K. Ebselen decreases ozone-induced pulmonary inflammation in rats. Lung 2000; 178:225-234.
127. Ren X, Xue Y, Liu J, Zhang K, Zheng J, Luo G, Guo C, Mu Y, Shen J. A novel cyclodextrin-derived tellurium compound with glutathione peroxidase activity. Chem biochem 2002; 3:356-363.
128. Chang LY, Subramaniam M, Yoder BA, Day BJ, Ellison MC, Sunday ME, Crapo JD. A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2003; 167: 57-64.
129. Buhl R, Vogelmeier C, Critenden M, Hubbard RC, Hoyt RF, Wilson EM, Cantin AM, Crystal RG. Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosol. Proc Natl Acad Sci USA 1990; 87:4063-4067.
130. Stabler SP, Morton RL, Winski SL, Allen RH, White CW. Effects of parenteral cysteine and glutathione feeding in a baboon model of severe prematurity. Am J Clin Nutr 2000; 72:1548-1557.
131. Anderson ME, Meister A. Intracellular delivery of cysteine. Methods Enzymol 1987; 143:313-325.
132. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6:593-597.
133. Winterbourn CC, Metodiewa D. Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide. Free Radic Biol Med 1999; 27:322-328.
134. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986; 1:31-42.
135. Phelps DT, Deneke SM, Daley DL, Fanburg BL. Elevation of glutathione levels in bovine pulmonary artery endothelial cells by N-acetylcysteine. Am J Respir Cell Mol Biol 1992; 7:293-299.
136. Shattuck KE, Rassin DK, Grinnell CD. N-acetylcysteine protects from glutathione depletion in rats exposed to hyperoxia. J Parenter Enteral Nutr 1998; 22:228-233.
137. Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 1995; 346:547-552.
138. Uttamsingh V, Baggs RB, Krenitsky DM, AndersMW. Immunohistochemical localization of the acylases that catalyze the deacetylation of N-acetyl-l-cysteine and haloalkene-derived mercapturates. Drug Metab Dispos 2000; 28:625-632.
139. Traber J, Suter M, Walter P, Richter C. In vivo modulation of total and mitochondrial glutathione in rat liver. Depletion by phorone and rescue by N-acetylcysteine. Biochem Pharmacol 1992; 43:961-964.
140. Will Y, Fischer KA, Horton RA, Kaetzel RS, Brown MK, Hedstrom O, Lieberman MW, Reed DJ. Gamma-glutamyltranspeptidase-deficient knockout mice as a model to study the relationship between glutathione status, mitochondrial function, and cellular function. Hepatology 2000; 32:740-749.
141. Asikainen TM, Huang TT, Taskinen E, Levonen AL, Carlson E, Lapatto R, Epstein CJ, Raivio KO. Increased sensitivity of homozygous Sod2 mutant mice to oxygen toxicity. Free Radic Biol Med 2002; 32:175-186.
142. Langley SC, Kelly FJ. N-acetylcysteine ameliorates hyperoxic lung injury in the preterm guinea pig. Biochem Pharmacol 1993; 45:841-846.
143. Davreux CJ, Soric I, Nathens AB, Watson RW, McGilvray ID, Suntres ZE, Shek PN, Rotstein OD. N-acetyl cysteine attenuates acute lung injury in the rat. Shock 1997; 8:432-438.
144. Suter PM, Domenighetti G, Schaller MD, Laverriere MC, Ritz R, Perret C. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest 1994; 105: 190-194.
145. Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, Wright PE. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The antioxidant in ARDS study group. Chest 1997; 112:164-172.
146. Domenighetti G, Suter PM, Schaller MD, Ritz R, Perret C. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care 1997; 12:177-182.
147. Ahola T, Lapatto R, Raivio KO, Selander B, Stigson L, Jonsson B, Jonsbo F, EsbergG, Stovring S, Kjartansson S, Stiris T, Lossius K, Virkola K, Fellman V. N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. J Pediatr 2003; 143:713-719.
148. Cortijo J, Cerda-Nicolas M, Serrano A, Bioque G, Estrela JM, Santangelo F, Esteras A, Llombart-Bosch A, Morcillo EJ. Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats. Eur Respir J 2001; 17: 1228-1235.
149. Hagiwara SI, Ishii Y, Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med 2000; 162:225-231.
150. Weinbroum AA, Kluger Y, Abraham RB, Shapira I, Karchevski E, Rudick V. Lung preconditioning with N-acetyl-l-cysteine prevents reperfusion injury after liver no flow-reflow: a dose-response study. Transplantation 2001; 71:300-306.
151. Levy MA, Sikorski B, Bray TM. Selective elevation of glutathione levels in target tissues with L-2-oxothiazolidine-4-carboxylate (OTC) protects against hyperoxia-induced lung damage in protein-energy malnourished rats: implications for a new treatment strategy. J Nutr 1998; 128:671-676.
152. Darlow BA, Winterbourn CC, Inder TE, Graham PJ, Harding JE, Weston PJ, Austin NC, Elder DE, Mogridge N, Buss IH, Sluis KB. The effect of selenium supplementation on outcome in very low birth weight infants: a randomized controlled trial. The New Zealand neonatal study group.J Pediatr 2000; 136:473-480.
153. Das KC, Lewis-Molock Y, White CW. Activation of NF-kappa B and elevation of MnSOD gene expression by thiol reducing agents in lung adenocarcinoma (A549) cells. Am J Physiol Lung Cell Mol Physiol 1995; 269: L588-L602.
154. deLemos RA, Roberts RJ, Coalson JJ, deLemos JA, Null DMJ, Gerstmann DR. Toxic effects associated with the administration of deferoxamine in the premature baboon with hyaline membrane disease. Am J Dis Child 1990; 144:915-919.
155. Watts JL, Milner R, Zipursky A, Paes B, Ling E, Gill G, Fletcher B, Rand C. Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1500 g birth weight. Eur Respir J 1991; 4: 188-190.
156. Ehrenkranz RA, Ablow RC, Warshaw JB. Effect of vitamin E on the development of oxygen-induced lung injury in neonates. Ann NY Acad Sci 1982; 393:452-466.
157. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR, Korones SB, Fanaroff AA. Vitamin A supplementation for extremely-low-birth-weight infants. National institute of child health and human development neonatal research network. N Engl J Med 1999; 340:1962-1968.
158. Langford SD, Bidani A, Postlethwait EM. Ozone-reactive absorption by pulmonary epithelial lining fluid constituents. Toxicol Appl Pharmacol 1995; 132:122-130.
159. Ding L, Liu Z, Zhu Z, Luo G, Zhao D, Ni J. Biochemical characterization of selenium-containing catalytic antibody as a cytosolic glutathione peroxidase mimic. Biochem J 1998; 332:251-255.
160. Ren X, Gao S, You D, Huang H, Liu Z, Mu Y, Liu J, Zhang Y, Yan G, Luo G, Yang T, Shen J. Cloning and expression of a single-chain catalytic antibody that acts as a glutathione peroxidase mimic with high catalytic efficiency. Biochem J 2001; 359:369-374.
161. Su D, Ren X, You D, Li D, Mu Y, Yan G, Zhang Y, Luo Y, Xue Y, Shen J, Liu Z, Luo G. Generation of three selenium-containing catalytic antibodies with high catalytic efficiency using a novel hapten design method. Arch Biochem Biophys 2001; 395:177-184.
162. Luo X, Sedlackova L, Belcastro R, Cabacungan J, Lye SJ, Tanswell AK. Effect of the 21-aminosteroid U74389G on oxygen-induced free radical production, lipid peroxidation, and inhibition of lung growth in neonatal rats. Pediatr Res 1999; 46:215-223.
163. 2-mediated pulmonary hypertension in neonatal rats: a role for products of lipid peroxidation. Pediatr Res 2000; 48:289-298.
164. Takeyoshi I, Iwanami K, Kamoshita N, Takahashi T, Kobayashi J, Tomizawa N, Kawashima Y, Matsumoto K, Morishita Y. Effect of lazaroid U-74389G on pulmonary ischemia-reperfusion injury in dogs. J Invest Surg 2001; 14:83-92.
165. Kuwaki K, Komatsu K, Sohma H, Abe T. Lazaroid U74389G ameliorates ischemia-reperfusion injury in the rat lung transplant model. Ann Thorac Cardiovasc Surg 1999; 5:11-17.
166. Hillinger S, Schmid RA, Stammberger U, Boehler A, Schob OM, Zollinger A, Weder W. Donor and recipient treatment with the Lazaroid U-74006F do not improve post-transplant lung function in swine. Eur J Cardiothorac Surg 1999; 15:475-480.
167. Hallman M, Glumoff V, Rämet M. Surfactant in respiratory distress syndrome and lung injury. Comp Biochem Physiol A Mol Integr Physiol 2001; 129:287-294.
168. Bridges JP, Davis HW, Damodarasamy M, Kuroki Y, Howles G, Hui DY, McCormack FX. Pulmonary surfactant proteins A and D are potent endogenous inhibitors of lipid peroxidation and oxidative cellular injury. J Biol Chem 2000; 275:38848-38855.
169. Blanco O, Catala A. Surfactant protein A inhibits the non-enzymatic lipid peroxidation of porcine lung surfactant. Prostaglandins Leukot Essent Fatty Acids 2001; 65:185-190.
170. Matalon S, Holm BA, Baker RR, Whitfield MK, Freeman BA. Characterization of antioxidant activities of pulmonary surfactant mixtures. Biochim Biophys Acta 1990; 1035:121-127.
171. Rosseau S, Hammerl P, Maus U, Gunther A, Seeger W, Grimminger F, Lohmeyer J. Surfactant protein A down-regulates proinflammatory cytokine production evoked by Candida albicans in human alveolar macrophages and monocytes. J Immunol 1999; 163:4495-4502.
172. Yoshida M, Korfhagen TR, Whitsett JA. Surfactant protein D regulates NFkappa B and matrix metalloproteinase production in alveolar macrophages via oxidant-sensitive pathways. J Immunol 2001; 166:7514-7519.
173. McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest 2002; 109:707-712.
174. Crouch E, Wright JR. Surfactant proteins a and d and pulmonary host defense. Annu Rev Physiol 2001; 63:521-554.
175. Mason RJ, Greene K, Voelker DR. Surfactant protein A and surfactant protein D in health and disease. Am J Physiol 1998; 275:L1-L13.
176. Kessler DL, Truog WE, Murphy JH, Palmer S, Standaert TA, Woodrum DE, Hodson WA. Experimental hyaline membrane disease in the premature monkey: effects of antenatal dexamethasone. Am Rev Respir Dis 1982; 126:62-69.
177. 2exposure. Pediatr Res 1992; 32:215-221.
178. Crowley P. Prophylactic corticosteroids for preterm birth (Cochrane review). Cochrane Database Syst Rev 2000; 2:CD000065.
179. Frank L, Lewis PL, Sosenko IR. Dexamethasone stimulation of fetal rat lung antioxidant enzyme activity in parallel with surfactant stimulation. Pediatrics 1985; 75:569-574.
180. Clerch LB, Iqbal J, Massaro D. Perinatal rat lung catalase gene expression: influence of corticosteroid and hyperoxia. Am J Physiol Lung Cell Mol Physiol 1991; 260:L428-L433.
181. Halliday HL, Ehrenkranz RA. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants (Cochrane review). Cochrane Database Syst Rev 2001; 2:CD001145.
182. Massaro GD, Massaro D. Retinoic acid treatment partially rescues failed septation in rats and in mice. Am J Physiol Lung Cell Mol Physiol 2000; 278: L955-L960.
183. 2exposure. Pediatr Res 1992; 32: 407-411.
184. Chen Y, Whitney PL, Frank L. Negative regulation of antioxidant enzyme gene expression in the developing fetal rat lung by prenatal hormonal treatments. Pediatr Res 1993; 33:171-176.
185. Ballard RA, Ballard PL, Cnaan A, Pinto-Martin J, Davis DJ, Padbury JF, Phibbs RH, Parer JT, Hart MC, Mannino FL, Sawai SK. Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants. North American thyrotropin-releasing hormone study group. N Engl J Med 1998; 338:493-498.
186. Eber E, Zach MS. Long term sequelae of bronchopulmonary dysplasia (chronic lung disease of infancy). Thorax 2001; 56:317-323.
187. Van Marter LJ, Allred EN, Leviton A, Pagano M, Parad R, Moore M. Antenatal glucocorticoid treatment does not reduce chronic lung disease among surviving preterm infants. J Pediatr 2001; 138:198-204.
188. Saugstad OD. Resuscitation with room-air or oxygen supplementation. Clin Perinatol 1998; 25:741-756.
189. Vento M, Asensi M, Sastre J, Garcia-Sala F, Viña J. Six years of experience with the use of room air for the resuscitation of asphyxiated newly born term infants. Biol Neonate 2001; 79:261-267.
190. Kinsella JP, Abman SH. Inhaled nitric oxide: current and future uses in neonates. Semin Perinatol 2000; 24:387-395.
191. Haataja R, Marttila R, Uimari P, Löfgren J, Rämet M, Hallman M. Respiratory distress syndrome: evaluation of genetic susceptibility and protection by transmission disequilibrium test. Hum Genet 2001; 109:351-355.
192. Clark DA, Pincus LG, Oliphant M, Hubbell C, Oates RP, Davey FR. HLAA2 and chronic lung disease in neonates. JAMA 1982; 248:1868-1869.
193. Cho HY, Jedlicka AE, Reddy SP, Zhang LY, Kensler TW, Kleeberger SR. Linkage analysis of susceptibility to hyperoxia. Nrf2 is a candidate gene. Am J Respir Cell Mol Biol 2002; 26:42-51.
194. Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY, Kleeberger SR. Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002; 26:175-182.
195. Kleeberger SR, Reddy S, Zhang LY, Jedlicka AE. Genetic susceptibility to ozone-induced lung hyperpermeability: role of toll-like receptor 4. Am J Respir Cell Mol Biol 2000; 22:620-627.
196. Flaherty DM, Monick MM, Hunninghake GW. AP endonucleases and the many functions of Ref-1. Am J Respir Cell Mol Biol 2001; 25:664-667.
197. He YH II, Wu M, Kobune M, Xu Y, Kelley MR, Martin WJ. Expression of yeast apurinic=apyrimidinic endonuclease (APN1) protects lung epithelial cells from bleomycin toxicity. Am J Respir Cell Mol Biol 2001; 25:692-698.
198. Prieto-AlamoMJ, Laval F. Overexpression of the humanHAP1 protein sensitizes cells to the lethal effect of bioreductive drugs. Carcinogenesis 1999; 20:415-419.
199. Grishko V, Solomon M, Wilson GL, LeDoux SP, Gillespie MN. Oxygen radical-induced mitochondrial DNA damage and repair in pulmonary vascular endothelial cell phenotypes. Am J Physiol Lung Cell Mol Physiol 2001; 280:L1300-L1308.
200. Helt CE, Rancourt RC, Staversky RJ, O’Reilly MA. p53-dependent induction of p21(Cip1=WAF1=Sdi1) protects against oxygen-induced toxicity. Toxicol Sci 2001; 63:214-222.
201. Rancourt RC, Keng PC, Helt CE, O’Reilly MA. The role of p21(CIP1= WAF1) in growth of epithelial cells exposed to hyperoxia. Am J Physiol Lung Cell Mol Physiol 2001; 280:L617-L626.
202. O’Reilly MA, Staversky RJ, Watkins RH, Reed CK, de Mesy Jensen KL, Finkelstein JN, Keng PC. The cyclin-dependent kinase inhibitor p21 protects the lung from oxidative stress. Am J Respir Cell Mol Biol 2001; 24:703-710.
203. Panos RJ, Bak PM, Simonet WS, Rubin JS, Smith LJ. Intratracheal instillation of keratinocyte growth factor decreases hyperoxia-induced mortality in rats. J Clin Invest 1995; 96:2026-2033.
204. 2exposure. Am J Physiol 1998; 275:L780-L787.
205. Vivekananda J, Awasthi V, Awasthi S, Smith DB, King RJ. Hepatocyte growth factor is elevated in chronic lung injury and inhibits surfactant metabolism. Am J Physiol Lung Cell Mol Physiol 2000; 278:L382-L392.
206. Ware LB, Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol 2002; 282:L924-L940.
207. Bast A, Haenen GR, Doelman CJ. Oxidants and antioxidants: state of the art. Am J Med 1991; 91:2S-13S.
208. Dalton TP, Shertzer HG, Puga A. Regulation of gene expression by reactive oxygen. Annu Rev Pharmacol Toxicol 1999; 39:67-101.
209. Jankov RP, Negus A, Tanswell AK. Antioxidants as therapy in the newborn: some words of caution. Pediatr Res 2001; 50:681-687.
210. White CW, Avraham KB, Shanley PF, Groner Y. Transgenic mice with expression of elevated levels of copper-zinc superoxide dismutase in the lungs are resistant to pulmonary oxygen toxicity. J Clin Invest 1991; 87:2162-2168.
211. Ho YS. Transgenic models for the study of lung biology and disease. Am J Physiol Lung Cell Mol Physiol 1994; 266:L319-L353.
212. Elroy SO, Bernstein Y, Groner Y. Overproduction of human Cu=Zn-superoxide dismutase in transfected cells: extenuation of paraquat-mediated cytotoxicity and enhancement of lipid peroxidation. EMBO J 1986; 5:615-622.
213. de Haan JB, Cristiano F, Iannello R, Bladier C, Kelner MJ, Kola I. Elevation in the ratio of Cu=Zn-superoxide dismutase to glutathione peroxidase activity induces features of cellular senescence and this effect is mediated by hydrogen peroxide. Hum Mol Genet 1996; 5:283-292.
214. Ilizarov AM, Koo HC, Kazzaz JA, Mantell LL, Li Y, Bhapat R, Pollack S, Horowitz S, Davis JM. Overexpression of manganese superoxide dismutase protects lung epithelial cells against oxidant injury. Am J Respir Cell Mol Biol 2001; 24:436-441.
215. Danel C, Erzurum SC, Prayssac P, Eissa NT, Crystal RG, Herve P, Baudet B, Mazmanian M, Lemarchand P. Gene therapy for oxidant injury-related diseases: adenovirus-mediated transfer of superoxide dismutase and catalase cDNAs protects against hyperoxia but not against ischemia-reperfusion lung injury. Hum Gene Ther 1998; 9:1487-1496.
216. Gardner PR, Raineri I, Epstein LB, White CW. Superoxide radical and iron modulate aconitase activity in mammalian cells. J Biol Chem 1995; 270: 13399-13405.
217. Gardner PR, Nguyen DD, White CW. Aconitase is a sensitive and critical target of oxygen poisoning in cultured mammalian cells and in rat lungs. Proc Natl Acad Sci USA 1994; 91:12248-12252.
218. Ahmad S, White CW, Chang LY, Schneider BK, Allen CB. Glutamine protects mitochondrial structure and function in oxygen toxicity. Am J Physiol Lung Cell Mol Physiol 2001; 280:L779-L791.
219. Van Remmen H, Williams MD, Guo Z, Estlack L, Yang H, Carlson EJ, Epstein CJ, Huang TT, Richardson A. Knockout mice heterozygous for Sod2 show alterations in cardiac mitochondrial function and apoptosis. Am J Physiol Heart Circ Physiol 2001; 281:H1422-H1432.
220. Huang TT, Carlson EJ, Kozy HM, Mantha S, Goodman SI, Ursell PC, Epstein CJ. Genetic modification of prenatal lethality and dilated cardiomyopathy in Mn superoxide dismutase mutant mice. Free Radic Biol Med 2001; 31:1101-1110.
221. Wong GH. Protective roles of cytokines against radiation: induction of mitochondrial MnSOD. Biochim Biophys Acta 1995; 1271:205-209.
222. Bai J, Rodriguez AM, Melendez JA, Cederbaum AI. Overexpression of catalase in cytosolic or mitochondrial compartment protects HepG2 cells against oxidative injury. J Biol Chem 1999; 274:26217-26224.
223. Schriner SE, Smith AC, Dang NH, Fukuchi K, Martin GM. Overexpression of wild-type and nuclear-targeted catalase modulates resistance to oxidative stress but does not alter spontaneous mutant frequencies at APRT. Mutat Res 2000; 449:21-31.
224. McDonald RJ, Berger EM, White CW, White JG, Freeman BA, Repine JE. Effect of superoxide dismutase encapsulated in liposomes or conjugated with polyethylene glycol on neutrophil bactericidal activity in vitro and bacterial clearance in vivo. Am Rev Respir Dis 1985; 131:633-637.
225. Nelson SK, Bose SK, McCord JM. The toxicity of high-dose superoxide dismutase suggests that superoxide can both initiate and terminate lipid peroxidation in the reperfused heart. Free Radic Biol Med 1994; 16:195-200.